Unexpected brain atrophy following administration of intratumoral interferon alpha-2b for cystic craniopharyngioma: A case report

Khadiga Elfadil Ahmed Mohammed, Kellie R Alleyne Mike, Jeannette Parkes
2013 International Journal of Case Reports and Images  
the use of intracystic treatments is relatively new in the treatment of craniopharyngioma and has the potential for decreased morbidity and long-term control in patients with recurrent cysts after radiotherapy as well as delaying radiotherapy treatment in young children. We describe a case in which the therapeutic use of interferon alpha-2b (IFNa-2b) was associated with an adverse effect that has not yet been documented in the medical literature. case report: An eight-year-old boy with a
more » ... d boy with a history of a craniopharyngioma was presented with radiological evidence of recurrence. He was first diagnosed at the age of eight months and had undergone repeated subtotal resections. At the age of three, he also received adjuvant radiotherapy after one of these resections. On this presentation of recurrence, a decision was made to offer him intracystic treatment with IFNa-2b. Although the typical pre-treatment leakage test was positive, the planned treatment decision was maintained following extensive multi-disciplinary consult with both local and international teams who advised that any
doi:10.5348/ijcri-2013-12-419-cr-13 fatcat:g4rukvwgtbgn7alhcl7wmjhg4i